EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Current Therapeutic Strategies and Future Prospects

Yukina Mizuno Yokoyama, Ryu Watanabe iD, Tomohiro Yamaguchi iD, Ryuhei Ishihara, Mayu Shiomi, Yuya Fujita, Masao Katsushima, Kazuo Fukumoto iD, Yoichiro Haji, Shinsuke Yamada, Motomu Hashimoto

Biomolecules · 13.01.2026 · 16 (1) · 140

DOI: 10.3390/biom16010140 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 13.01.2026. Verfasst von Yukina Mizuno Yokoyama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-Ku, Osaka 545-8585, Japan. Hauptthemen laut MEDLINE: Connective Tissue Diseases, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) is a severe form of pulmonary hypertension with poor prognosis. It most commonly arises in systemic sclerosis (SSc), followed by systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD). Its pathogenesis involves a complex interplay of immune dysregulation, chronic inflammation, endothelial injury, vascular remodeling, and fibrosis. Although vasodilators targeting the endothelin, nitric oxide, and prostacyclin pathways remain the therapeutic backbone, newer agents—including the activin signal inhibitor sotatercept and inhaled treprostinil—have expanded treatment options. Immune-targeted therapies such as glucocorticoids, cyclophosphamide, mycophenolate mofetil, rituximab, and IL-6 receptor inhibitors may benefit inflammation-dominant PAH phenotypes, while fibrotic phenotypes continue to demonstrate limited responsiveness. In addition to brain natriuretic peptide (BNP), N-terminal (NT)-proBNP and disease-specific autoantibodies, emerging biomarkers show promise for early detection, risk stratification, and personalized treatment, though validation in CTD-PAH is lacking. Advances in animal models replicating immune-mediated vascular injury and fibrosis have further improved mechanistic understanding. Despite these developments, substantial unmet needs remain, including the absence of disease-specific therapeutic strategies, limited biomarker integration into clinical practice, and a scarcity of large, well-designed trials targeting individual CTD subtypes. Addressing these gaps will be essential for improving prognosis in patients with CTD-PAH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Connective Tissue DiseasesPulmonary Arterial HypertensionHumansAnimalsBiomarkersScleroderma, SystemicHypertension, Pulmonary

Stichwörter der Autor:innen

animal modelbiomarkerconnective tissue diseasepulmonary arterial hypertensionsystemic sclerosis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-Ku, Osaka 545-8585, Japan.
  • Department of Rheumatology, Daido Hospital, Nagoya 457-8511, Japan.
  • Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.

ORCID-Profile: Ryu Watanabe, Tomohiro Yamaguchi, Kazuo Fukumoto

Zitieren

APA

Yokoyama, Y. M., Watanabe, R., Yamaguchi, T., Ishihara, R., Shiomi, M., Fujita, Y., Katsushima, M., Fukumoto, K., Haji, Y., Yamada, S., & Hashimoto, M. (2026). Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Current Therapeutic Strategies and Future Prospects. Biomolecules, 16(1), 140. https://doi.org/10.3390/biom16010140

Vancouver

Yokoyama YM, Watanabe R, Yamaguchi T, Ishihara R, Shiomi M, Fujita Y, et al. Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Current Therapeutic Strategies and Future Prospects. Biomolecules. 2026;16(1):140. doi:10.3390/biom16010140

BibTeX
@article{Yokoyama2026,
  author = {Yokoyama, Yukina Mizuno and Watanabe, Ryu and Yamaguchi, Tomohiro and Ishihara, Ryuhei and Shiomi, Mayu and Fujita, Yuya and Katsushima, Masao and Fukumoto, Kazuo and Haji, Yoichiro and Yamada, Shinsuke and Hashimoto, Motomu},
  title = {Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: Current Therapeutic Strategies and Future Prospects},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {1},
  pages = {140},
  doi = {10.3390/biom16010140}
}
Kostenlos starten →